Evidence map›Paper›PMID 29844588›Full record

ReviewNature reviews. Gastroenterology & hepatology2018

Noninvasive biomarkers in NAFLD and NASH - current progress and future promise.

Vincent Wai-Sun Wong, Leon A Adams, Victor de Lédinghen, Grace Lai-Hung Wong, Silvia Sookoian

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Gastroenterology & hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 330 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
330citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05618626 narecruitingnot on this mapstarted 2021, after this paper: background citation

Cardiovascular Diseases (CVD) and Nonalcoholic Fatty Liver Diseases (NAFLD) Among Gallstone and Cholecystectomy Patients and the Impact of a Novel Diet and Muscle Training Program

TypeinterventionalSponsorPontificia Universidad Catolica de ChileRan2021 to 2025Enrolled300ConditionsNon-Alcoholic Fatty Liver Disease, Gallstone DiseaseArmsPhysical exercise and dietary intervention for NAFLD
NCT06843421 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry: A Retrospective Multicenter Cross-Sectional Study (K-MASLD Registry)

TypeobservationalSponsorKorea UniversityRan2025 to 2025Enrolled6,000ConditionsMetabolic Dysfunction-Associated Steatotic Liver Disease, Cardiovascular Diseases
3 · Its place in the literature

Who cites it

330 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Serum Ferritin and Non-alcoholic Fatty Liver Disease: A Meta-analysis and Systematic Review.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Guideline
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Observational
  19. MAFLD/MASLD: Past, Present, and Future.Journal of gastroenterology and hepatology · 2026
    Review
  20. Time-Varying Impact of Steatosis and Alcohol on Mortality: A Marginal Structural Model of the Canadian Longitudinal Study on Aging.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article

270 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vincent Wai-Sun WongDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China. wongv@cuhk.edu.hk.ORCID http://orcid.org/0000-0003-2215-9410
Leon A AdamsSchool of Medicine and Pharmacology, The University of Western Australia, Nedlands, Australia.
Victor de LédinghenHepatology Unit, University Hospital, CHU Bordeaux, Pessac, France.
Grace Lai-Hung WongDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.ORCID http://orcid.org/0000-0002-2863-9389
Silvia SookoianUniversity of Buenos Aires, Institute of Medical Research A Lanari, Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is the most common chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH) is the active form of NAFLD, with hepatic necroinflammation and faster fibrosis progression. With an increasing number of patients developing NASH-related end-stage liver disease and pharmacological treatments on the horizon, there is a pressing need to develop NAFLD and NASH biomarkers for prognostication, selection of patients for treatment and monitoring. This requirement is particularly true as liver biopsy utility is limited by its invasive nature, poor patient acceptability and sampling variability. This article reviews current and potential biomarkers for different features of NAFLD, namely, steatosis, necroinflammation and fibrosis. For each biomarker, we evaluate its accuracy, reproducibility, responsiveness, feasibility and limitations. We cover biochemical, imaging and genetic biomarkers and discuss biomarker discovery in the omics era.

Indexed as

BiomarkersBiopsyCytokinesDiagnosis, DifferentialEarly DiagnosisElasticity Imaging TechniquesFerritinsForecastingGenetic MarkersHormonesHumansInsulinKeratin-18Lipid MetabolismLiver CirrhosisMagnetic Resonance ImagingBiomarkersCytokinesFerritinsGenetic MarkersHormonesInsulinKeratin-18TIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1

Identifiers

PMID29844588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.